← All candidates
Three insider buys in the last year — $96.9K in all.
51 filings on record.
IPSCCentury Therapeutics, Inc.
NasdaqCM · Healthcare · $336.80M
$1.86
-6.06% today
Three insider buys in the last year — $96.9K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 3 buys● 12 sells◆ 9 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$336.80M
Float
101.3M
56% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Scientific Officer
Cowan Chad
Bought $49.3K on Dec 22 — 58,060 sh @ $0.8483, held direct, 5.6% of their stake.
First Form 4 on file
President and CEO
Pfeiffenberger Brent
Bought $30.4K on Dec 12 — 52,000 sh @ $0.5837, held direct, 1.6% of their stake.
First Form 4 on file
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
33 more transactions on Pro →Context
Wall St
$4.75 avg target
+155.4% vs today · 4 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q2 '26−$0.11 act+$0.00
Q1 '26−$0.11 act+$0.06
Q4 '25−$0.25 act+$0.05
Q3 '25−$0.32 act+$0.07
Coverage
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific CongressesInsider Monkey · 07-14Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn SituationSimply Wall St. · 06-13Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813Insider Monkey · 06-10H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)Insider Monkey · 05-01
The file stays open
51 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice